Search clinical trials for: Anti-PlGF recombinant monoclonal antibody, 4mg dose

Total 1872 results

National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | HER2/Neu Positive

United States, Puerto Rico
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Relapsed Classic Hodgkin Lymphoma

United States
John Reneau

Active, not recruiting

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Classic Hodgkin Lymphoma

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.

Locally Advanced Unresectable Esophageal Squamous Carcinoma

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditions

United States
University of California, Davis

Unknown

Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
Zhejiang Cancer Hospital

Completed

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Hangzhou Hanx Biopharmaceuticals, Ltd.
Wuhan Hanxiong Bioscience, Ltd.

Active, not recruiting

Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Sun Yat-sen University

Not yet recruiting

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL (SPENT)

Extranodal NK/T-cell Lymphoma, Nasal Type

China
National Cancer Institute (NCI)

Completed

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

Recurrent Osteosarcoma | Metastatic Osteosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Recurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditions

United States
Stanford University
National Cancer Institute (NCI)

Terminated

Ipilimumab and Local Radiation for Selected Solid Tumors

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
McMaster University
St. Joseph's Healthcare Hamilton; Teva Pharmaceuticals USA

Completed

Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

Severe Persistent Asthma | Eosinophilic Bronchitis

Canada
Astellas Pharma S.A.S.

Completed

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE)

Clostridium Difficile Infection

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer

Sarcoma | Neuroblastoma

United States
Northwestern University
Seagen Inc.

Terminated

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell... and other conditions

United States
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Completed

3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals

Human Immunodeficiency Virus

United States
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

The ESG Integrity Study: Effect of Proton Pump Inhibitors on the Structural Integrity of Endoscopic Sleeve Gastroplasty (ESGIS)

Obesity

Italy
Tiziana Life Sciences LTD

Withdrawn

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Crohn's Disease
St. Anna Kinderkrebsforschung
Charite University, Berlin, Germany; Istituto Giannina Gaslini; St. Anna Children...

Completed

ch14.18/CHO Bridging Study

Neuroblastoma

Italy, Austria, Germany
Patrys Ltd.

Completed

Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Drug Safety

Germany
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Terminated

S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

Lung Cancer

United States, Canada
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Assiut University

Unknown

Oral Omeprazole in Bleeding Peptic Ulcer

Bleeding Peptic Ulcer
Matthias Schwab

Terminated

Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing (GERD)

Gastroesophageal Reflux

Germany
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
Qilu Pharmaceutical Co., Ltd.

Completed

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Breast Cancer

China
MAXVAX Biotechnology Limited Liability Company
Henan Center for Disease Control and Prevention

Active, not recruiting

Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Herpes Zoster

China
Yuhan Corporation

Completed

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

Healthy

Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Glioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain Neoplasm

United States, Canada
National Cancer Institute (NCI)

Completed

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Uterine Carcinosarcoma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Endometrial Serous Adenocarcinoma | Lung Carcinoid Tumor | Metastatic... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Stage IV Pancreatic Cancer

United States
Ruijin Hospital

Not yet recruiting

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (ENKTL)

NK-T-Cell Lymphoma, Extranodal

China
Abbott

Terminated

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma | Metastases

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma

United States
University of Washington
Bayer

Terminated

Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Lymphoid Leukemia

United States
National Cancer Institute (NCI)

Completed

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Masonic Cancer Center, University of Minnesota

Terminated

Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia

Leukemia

United States

Search clinical trials for: Anti-PlGF recombinant monoclonal antibody, 4mg dose

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations